Thank you for your inquiry Dave. I have concerns regarding future needs for cash. $17 million seems insignificant for the expansion, and FDA requirements in 2023 and beyond. I fear sales will not create enough dollars to satisfy requirements. Therefore it is my hope a better way of raising funds than dilution, as done twice before at give away prices can be explored. Additionally shareholders in the lower "48 were excluded from participation in previous share sales. Meaning our holdings were devalued without opportunity to participate in both offerings. I believe more creative sources can and should be explored and implemented. Such as commercial banking loans, loans or share sales to "partners" or share sales to investment bankers.
Market Data 
Markets 
AI
